| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ocular Hypertension | 10 | 2022 | 43 | 3.020 |
Why?
|
| Retina | 13 | 2022 | 252 | 2.800 |
Why?
|
| Intraocular Pressure | 22 | 2021 | 143 | 2.790 |
Why?
|
| Retinal Degeneration | 6 | 2021 | 75 | 2.440 |
Why?
|
| Reperfusion Injury | 7 | 2016 | 320 | 2.260 |
Why?
|
| Aqueous Humor | 13 | 2013 | 51 | 1.850 |
Why?
|
| Retinal Ganglion Cells | 6 | 2021 | 72 | 1.830 |
Why?
|
| Trabecular Meshwork | 7 | 2013 | 22 | 1.500 |
Why?
|
| Retinal Pigment Epithelium | 8 | 2016 | 145 | 1.430 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2016 | 116 | 1.410 |
Why?
|
| Histone Deacetylases | 4 | 2016 | 99 | 1.400 |
Why?
|
| Electroretinography | 14 | 2021 | 122 | 1.310 |
Why?
|
| Sphingomyelin Phosphodiesterase | 4 | 2022 | 183 | 1.290 |
Why?
|
| Adenosine | 12 | 2006 | 165 | 1.210 |
Why?
|
| Ischemic Preconditioning | 5 | 2016 | 31 | 1.210 |
Why?
|
| Blotting, Western | 15 | 2021 | 954 | 1.130 |
Why?
|
| Optic Disk | 3 | 2022 | 37 | 1.110 |
Why?
|
| Ciliary Body | 7 | 2009 | 52 | 1.080 |
Why?
|
| Retinal Diseases | 5 | 2011 | 40 | 1.060 |
Why?
|
| Retinal Vessels | 7 | 2016 | 74 | 0.950 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2022 | 86 | 0.930 |
Why?
|
| Animals | 67 | 2021 | 20881 | 0.930 |
Why?
|
| Eye | 5 | 2014 | 89 | 0.910 |
Why?
|
| Bradykinin | 4 | 2011 | 157 | 0.890 |
Why?
|
| Rats, Inbred BN | 12 | 2016 | 51 | 0.880 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 150 | 0.870 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 147 | 0.870 |
Why?
|
| Ceramides | 3 | 2022 | 578 | 0.860 |
Why?
|
| Prostaglandins F, Synthetic | 4 | 2008 | 8 | 0.840 |
Why?
|
| Morphine | 3 | 2012 | 76 | 0.820 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2021 | 626 | 0.810 |
Why?
|
| Disease Models, Animal | 15 | 2016 | 2550 | 0.790 |
Why?
|
| Cells, Cultured | 18 | 2016 | 2673 | 0.700 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2016 | 219 | 0.700 |
Why?
|
| Hydroxamic Acids | 4 | 2016 | 84 | 0.700 |
Why?
|
| Receptors, Opioid | 2 | 2011 | 60 | 0.690 |
Why?
|
| Antihypertensive Agents | 4 | 2014 | 498 | 0.690 |
Why?
|
| Receptors, Purinergic P1 | 5 | 1999 | 18 | 0.670 |
Why?
|
| Rabbits | 26 | 2016 | 509 | 0.660 |
Why?
|
| Histones | 3 | 2016 | 111 | 0.660 |
Why?
|
| Receptor, Bradykinin B2 | 3 | 2014 | 75 | 0.620 |
Why?
|
| Rats | 20 | 2016 | 5300 | 0.610 |
Why?
|
| Caspase 3 | 3 | 2016 | 233 | 0.600 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2008 | 145 | 0.580 |
Why?
|
| Dinoprost | 2 | 2008 | 27 | 0.570 |
Why?
|
| Pupil | 7 | 2000 | 51 | 0.560 |
Why?
|
| Muscle, Smooth | 3 | 2008 | 117 | 0.560 |
Why?
|
| Desipramine | 1 | 2016 | 47 | 0.550 |
Why?
|
| Receptor, Adenosine A1 | 2 | 2006 | 8 | 0.540 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2010 | 19 | 0.540 |
Why?
|
| Neuroprotection | 1 | 2016 | 28 | 0.530 |
Why?
|
| Heat-Shock Proteins | 3 | 2005 | 69 | 0.520 |
Why?
|
| Blood-Retinal Barrier | 5 | 2016 | 15 | 0.500 |
Why?
|
| Lysine | 1 | 2014 | 96 | 0.470 |
Why?
|
| Quinolines | 1 | 2014 | 48 | 0.460 |
Why?
|
| Acetylation | 4 | 2016 | 94 | 0.460 |
Why?
|
| Eye Proteins | 8 | 2013 | 160 | 0.460 |
Why?
|
| Mice, Knockout | 6 | 2021 | 1692 | 0.450 |
Why?
|
| Histone Deacetylase 2 | 1 | 2013 | 7 | 0.450 |
Why?
|
| Immunohistochemistry | 8 | 2016 | 1174 | 0.440 |
Why?
|
| Nerve Growth Factors | 6 | 2013 | 75 | 0.430 |
Why?
|
| Hypertension | 1 | 2022 | 1535 | 0.430 |
Why?
|
| Protein Kinase C | 5 | 2011 | 270 | 0.430 |
Why?
|
| Anterior Eye Segment | 4 | 2006 | 13 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2007 | 1745 | 0.420 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 2791 | 0.420 |
Why?
|
| Purinergic P1 Receptor Agonists | 3 | 2001 | 7 | 0.420 |
Why?
|
| Anterior Chamber | 4 | 2009 | 20 | 0.410 |
Why?
|
| Enzyme Inhibitors | 6 | 2016 | 659 | 0.400 |
Why?
|
| Serpins | 6 | 2013 | 205 | 0.390 |
Why?
|
| Biological Assay | 1 | 2011 | 88 | 0.380 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2010 | 19 | 0.370 |
Why?
|
| Pigment Epithelium of Eye | 2 | 2007 | 28 | 0.350 |
Why?
|
| Cornea | 8 | 1996 | 76 | 0.350 |
Why?
|
| Transcription Factors | 3 | 2021 | 753 | 0.340 |
Why?
|
| Ischemia | 5 | 2022 | 229 | 0.340 |
Why?
|
| Aging | 1 | 2015 | 911 | 0.330 |
Why?
|
| Kallikrein-Kinin System | 1 | 2009 | 18 | 0.330 |
Why?
|
| Epithelial Cells | 1 | 2011 | 431 | 0.330 |
Why?
|
| Narcotics | 1 | 2009 | 65 | 0.320 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2016 | 507 | 0.320 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2008 | 28 | 0.310 |
Why?
|
| Phenylisopropyladenosine | 4 | 1997 | 6 | 0.310 |
Why?
|
| Cattle | 7 | 2006 | 475 | 0.310 |
Why?
|
| Signal Transduction | 6 | 2016 | 2689 | 0.300 |
Why?
|
| Iris | 4 | 1997 | 27 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 32 | 0.290 |
Why?
|
| Calcium | 5 | 2008 | 929 | 0.290 |
Why?
|
| Pilocarpine | 2 | 1999 | 9 | 0.280 |
Why?
|
| Enzyme Activation | 6 | 2016 | 791 | 0.270 |
Why?
|
| Male | 17 | 2016 | 37321 | 0.270 |
Why?
|
| Macular Edema | 2 | 2016 | 21 | 0.260 |
Why?
|
| Adrenergic alpha-Agonists | 4 | 2000 | 57 | 0.260 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 307 | 0.260 |
Why?
|
| Humans | 27 | 2022 | 68618 | 0.260 |
Why?
|
| Sympathetic Nervous System | 2 | 1997 | 81 | 0.250 |
Why?
|
| Astrocytes | 2 | 2021 | 270 | 0.240 |
Why?
|
| Hyperglycemia | 2 | 2016 | 158 | 0.240 |
Why?
|
| Neurons | 2 | 2003 | 881 | 0.240 |
Why?
|
| Administration, Topical | 8 | 2009 | 111 | 0.240 |
Why?
|
| Nuclear Proteins | 2 | 2005 | 271 | 0.230 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2004 | 10 | 0.230 |
Why?
|
| Valproic Acid | 2 | 2014 | 93 | 0.230 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 4 | 2011 | 95 | 0.230 |
Why?
|
| Female | 17 | 2014 | 38074 | 0.230 |
Why?
|
| Corneal Neovascularization | 1 | 2003 | 6 | 0.230 |
Why?
|
| Porphyrins | 1 | 2003 | 15 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2004 | 250 | 0.220 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 32 | 0.220 |
Why?
|
| Photochemotherapy | 1 | 2003 | 59 | 0.210 |
Why?
|
| Glaucoma | 4 | 2013 | 50 | 0.210 |
Why?
|
| Time Factors | 8 | 2019 | 4655 | 0.210 |
Why?
|
| Dipeptides | 3 | 2008 | 89 | 0.210 |
Why?
|
| Sphingomyelins | 1 | 2022 | 106 | 0.210 |
Why?
|
| Dinoprostone | 1 | 2003 | 110 | 0.200 |
Why?
|
| Cytokines | 3 | 2022 | 866 | 0.200 |
Why?
|
| Epinephrine | 3 | 1999 | 103 | 0.200 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2014 | 59 | 0.200 |
Why?
|
| Chronic Disease | 4 | 2016 | 1330 | 0.200 |
Why?
|
| Cell Survival | 3 | 2014 | 901 | 0.190 |
Why?
|
| Swine | 5 | 2014 | 672 | 0.190 |
Why?
|
| Cell Count | 1 | 2021 | 248 | 0.190 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 700 | 0.190 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 209 | 0.190 |
Why?
|
| Mice | 9 | 2015 | 8474 | 0.190 |
Why?
|
| Horner Syndrome | 1 | 2000 | 8 | 0.180 |
Why?
|
| Cell Death | 1 | 2021 | 329 | 0.180 |
Why?
|
| Clonidine | 1 | 2000 | 66 | 0.180 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2016 | 381 | 0.180 |
Why?
|
| Cyclic AMP | 7 | 2012 | 223 | 0.180 |
Why?
|
| Naloxone | 2 | 2011 | 56 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 247 | 0.180 |
Why?
|
| Tight Junctions | 2 | 2011 | 25 | 0.170 |
Why?
|
| Adrenergic Agonists | 1 | 1999 | 5 | 0.170 |
Why?
|
| Muscarinic Agonists | 1 | 1999 | 17 | 0.170 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 58 | 0.170 |
Why?
|
| Neuroprotective Agents | 2 | 2014 | 317 | 0.170 |
Why?
|
| Norepinephrine | 2 | 1997 | 276 | 0.170 |
Why?
|
| Bradykinin B2 Receptor Antagonists | 2 | 2011 | 13 | 0.170 |
Why?
|
| RNA, Messenger | 5 | 2009 | 1664 | 0.170 |
Why?
|
| In Vitro Techniques | 6 | 2009 | 765 | 0.170 |
Why?
|
| Tetrahydronaphthalenes | 2 | 1990 | 20 | 0.160 |
Why?
|
| Naphthalenes | 2 | 1990 | 47 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 175 | 0.160 |
Why?
|
| Filtering Surgery | 1 | 1998 | 1 | 0.160 |
Why?
|
| Caspases | 2 | 2012 | 194 | 0.160 |
Why?
|
| Narcotic Antagonists | 2 | 2011 | 184 | 0.160 |
Why?
|
| Daunorubicin | 1 | 1998 | 20 | 0.160 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2019 | 101 | 0.160 |
Why?
|
| Thiophenes | 2 | 1990 | 76 | 0.160 |
Why?
|
| Phorbol Esters | 1 | 1998 | 37 | 0.160 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 160 | 0.150 |
Why?
|
| Pyrroles | 2 | 2009 | 83 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 82 | 0.150 |
Why?
|
| Carcinogens | 1 | 1998 | 86 | 0.150 |
Why?
|
| Pancreatitis, Chronic | 1 | 2019 | 168 | 0.150 |
Why?
|
| Endothelial Growth Factors | 3 | 2002 | 25 | 0.150 |
Why?
|
| Cell Line | 3 | 2012 | 1752 | 0.150 |
Why?
|
| Lymphokines | 3 | 2002 | 49 | 0.150 |
Why?
|
| Macaca fascicularis | 3 | 2014 | 31 | 0.150 |
Why?
|
| Chlorides | 3 | 1986 | 68 | 0.150 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 120 | 0.140 |
Why?
|
| Ophthalmic Solutions | 4 | 2000 | 39 | 0.140 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2008 | 59 | 0.140 |
Why?
|
| Phenethylamines | 1 | 1996 | 20 | 0.140 |
Why?
|
| Theophylline | 3 | 2005 | 22 | 0.140 |
Why?
|
| Cricetulus | 2 | 2014 | 98 | 0.140 |
Why?
|
| CHO Cells | 2 | 2014 | 161 | 0.140 |
Why?
|
| Up-Regulation | 4 | 2006 | 682 | 0.130 |
Why?
|
| Protease Inhibitors | 2 | 2006 | 76 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 434 | 0.130 |
Why?
|
| Glycation End Products, Advanced | 2 | 2015 | 125 | 0.130 |
Why?
|
| Benzophenanthridines | 2 | 2008 | 5 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha | 2 | 1992 | 40 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2016 | 110 | 0.130 |
Why?
|
| Matrix Metalloproteinases | 2 | 2008 | 223 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2016 | 1040 | 0.120 |
Why?
|
| Acetyltransferases | 1 | 2014 | 49 | 0.120 |
Why?
|
| Retinal Neurons | 1 | 2014 | 9 | 0.120 |
Why?
|
| Bromobenzenes | 1 | 2014 | 4 | 0.120 |
Why?
|
| Benzophenones | 1 | 2014 | 12 | 0.120 |
Why?
|
| Papilledema | 1 | 2014 | 21 | 0.120 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 195 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 138 | 0.120 |
Why?
|
| Cyclodextrins | 1 | 1993 | 2 | 0.110 |
Why?
|
| beta-Cyclodextrins | 1 | 1993 | 5 | 0.110 |
Why?
|
| Immunoblotting | 3 | 2016 | 254 | 0.110 |
Why?
|
| Dopamine Agents | 2 | 1990 | 56 | 0.110 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2012 | 5 | 0.110 |
Why?
|
| Epithelium | 6 | 1993 | 172 | 0.110 |
Why?
|
| Aged | 5 | 2019 | 14862 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 63 | 0.110 |
Why?
|
| Middle Aged | 5 | 2019 | 21147 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 57 | 0.110 |
Why?
|
| Molecular Chaperones | 1 | 2013 | 81 | 0.110 |
Why?
|
| Cats | 5 | 2008 | 292 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 191 | 0.100 |
Why?
|
| Ocular Hypotension | 3 | 2001 | 10 | 0.100 |
Why?
|
| Immunotoxins | 1 | 1992 | 23 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 148 | 0.100 |
Why?
|
| Optic Nerve | 1 | 2012 | 55 | 0.100 |
Why?
|
| Species Specificity | 3 | 2008 | 303 | 0.100 |
Why?
|
| Inosine | 2 | 2003 | 6 | 0.100 |
Why?
|
| Homeostasis | 1 | 2013 | 291 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 710 | 0.100 |
Why?
|
| Membrane Potentials | 1 | 2011 | 200 | 0.100 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2011 | 25 | 0.100 |
Why?
|
| Tretinoin | 1 | 2011 | 92 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 64 | 0.090 |
Why?
|
| Retinaldehyde | 1 | 2011 | 115 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 3 | 2016 | 88 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2011 | 150 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 370 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2002 | 183 | 0.090 |
Why?
|
| Receptors, Adrenergic | 1 | 1990 | 68 | 0.090 |
Why?
|
| Lim Kinases | 1 | 2009 | 3 | 0.090 |
Why?
|
| Nifedipine | 1 | 1990 | 40 | 0.090 |
Why?
|
| Microglia | 1 | 2011 | 143 | 0.090 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2010 | 22 | 0.090 |
Why?
|
| Receptors, Dopamine | 1 | 1990 | 119 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2011 | 1200 | 0.090 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2010 | 74 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1293 | 0.090 |
Why?
|
| Proteins | 3 | 2002 | 474 | 0.080 |
Why?
|
| Apoptosis | 1 | 2016 | 1641 | 0.080 |
Why?
|
| Cataract | 1 | 2010 | 134 | 0.080 |
Why?
|
| Capsaicin | 1 | 1988 | 5 | 0.080 |
Why?
|
| Indoles | 2 | 2007 | 146 | 0.080 |
Why?
|
| Ergolines | 1 | 2008 | 19 | 0.080 |
Why?
|
| Uveitis, Anterior | 1 | 1988 | 15 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 455 | 0.080 |
Why?
|
| Gene Expression | 2 | 2009 | 770 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 4848 | 0.080 |
Why?
|
| Kinins | 1 | 2009 | 109 | 0.080 |
Why?
|
| Disease Progression | 1 | 2012 | 1038 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2013 | 46 | 0.080 |
Why?
|
| Age Factors | 2 | 2010 | 1864 | 0.080 |
Why?
|
| Blotting, Northern | 3 | 2003 | 189 | 0.080 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2005 | 10 | 0.080 |
Why?
|
| Thalidomide | 1 | 2008 | 24 | 0.080 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 63 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2009 | 178 | 0.080 |
Why?
|
| Sympathectomy | 2 | 1985 | 24 | 0.080 |
Why?
|
| Purinergic P1 Receptor Antagonists | 2 | 1999 | 10 | 0.080 |
Why?
|
| Cytoprotection | 2 | 2005 | 39 | 0.080 |
Why?
|
| Cell Line, Transformed | 2 | 2005 | 100 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2006 | 371 | 0.080 |
Why?
|
| Dopamine | 2 | 1994 | 474 | 0.070 |
Why?
|
| Kallikreins | 1 | 2009 | 323 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 59 | 0.070 |
Why?
|
| Sus scrofa | 1 | 2007 | 74 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2005 | 71 | 0.070 |
Why?
|
| Uveitis | 1 | 2007 | 13 | 0.070 |
Why?
|
| Protein Transport | 1 | 2008 | 280 | 0.070 |
Why?
|
| Quinazolines | 1 | 2007 | 70 | 0.070 |
Why?
|
| Nitric Oxide Donors | 1 | 2007 | 54 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2008 | 308 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 498 | 0.070 |
Why?
|
| Electric Impedance | 1 | 2007 | 131 | 0.070 |
Why?
|
| Phorbols | 1 | 1986 | 8 | 0.070 |
Why?
|
| Nitriles | 2 | 2009 | 68 | 0.070 |
Why?
|
| Biological Transport | 3 | 1998 | 210 | 0.070 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2006 | 22 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2005 | 42 | 0.070 |
Why?
|
| Type C Phospholipases | 1 | 2006 | 67 | 0.070 |
Why?
|
| Corneal Injuries | 1 | 1986 | 4 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 782 | 0.070 |
Why?
|
| S-Nitrosoglutathione | 1 | 2007 | 87 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 1447 | 0.070 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2005 | 2 | 0.070 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2005 | 2 | 0.070 |
Why?
|
| Half-Life | 2 | 1998 | 96 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1070 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 186 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3259 | 0.060 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 2 | 1996 | 2 | 0.060 |
Why?
|
| Fundus Oculi | 2 | 2016 | 33 | 0.060 |
Why?
|
| Fluorescein Angiography | 2 | 2016 | 57 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2005 | 16 | 0.060 |
Why?
|
| Cobalt | 1 | 2005 | 37 | 0.060 |
Why?
|
| Rheology | 1 | 2004 | 25 | 0.060 |
Why?
|
| Serotonin | 1 | 1985 | 144 | 0.060 |
Why?
|
| Adult | 3 | 2019 | 21403 | 0.060 |
Why?
|
| Vasodilator Agents | 2 | 1996 | 138 | 0.060 |
Why?
|
| Uridine Diphosphate | 1 | 2004 | 3 | 0.060 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Wound Healing | 1 | 1986 | 260 | 0.060 |
Why?
|
| Drainage | 1 | 2004 | 133 | 0.060 |
Why?
|
| Serum Albumin | 2 | 2015 | 104 | 0.060 |
Why?
|
| Drug Residues | 1 | 2003 | 6 | 0.060 |
Why?
|
| Serotonin Agents | 1 | 2003 | 13 | 0.060 |
Why?
|
| Detergents | 1 | 2003 | 34 | 0.060 |
Why?
|
| Prostheses and Implants | 1 | 2004 | 159 | 0.060 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2003 | 35 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2006 | 597 | 0.060 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2003 | 19 | 0.060 |
Why?
|
| Enkephalins | 1 | 2003 | 89 | 0.060 |
Why?
|
| Electric Stimulation | 2 | 1997 | 218 | 0.050 |
Why?
|
| Lasers | 1 | 2003 | 61 | 0.050 |
Why?
|
| Base Sequence | 1 | 2005 | 1015 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2013 | 236 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 134 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 215 | 0.050 |
Why?
|
| Theobromine | 2 | 1999 | 3 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 282 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 260 | 0.050 |
Why?
|
| Rats, Long-Evans | 1 | 2003 | 203 | 0.050 |
Why?
|
| Glutarates | 1 | 2002 | 6 | 0.050 |
Why?
|
| Triamcinolone Acetonide | 1 | 2002 | 10 | 0.050 |
Why?
|
| Quinoxalines | 3 | 1992 | 78 | 0.050 |
Why?
|
| Mitomycin | 1 | 2002 | 27 | 0.050 |
Why?
|
| Plasminogen | 1 | 2002 | 28 | 0.050 |
Why?
|
| Endothelin-1 | 1 | 2003 | 122 | 0.050 |
Why?
|
| Nictitating Membrane | 2 | 1992 | 15 | 0.050 |
Why?
|
| Fluorophotometry | 1 | 2001 | 1 | 0.050 |
Why?
|
| Phenanthridines | 1 | 2001 | 8 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2001 | 25 | 0.050 |
Why?
|
| Butadienes | 1 | 2001 | 26 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 88 | 0.050 |
Why?
|
| Alkaloids | 1 | 2001 | 40 | 0.050 |
Why?
|
| Biological Availability | 2 | 2008 | 79 | 0.050 |
Why?
|
| Yohimbine | 2 | 1992 | 41 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2002 | 181 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 272 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2001 | 82 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2003 | 2083 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 1999 | 567 | 0.050 |
Why?
|
| Glucose | 1 | 1982 | 307 | 0.050 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2000 | 17 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2000 | 80 | 0.050 |
Why?
|
| Biological Transport, Active | 3 | 1985 | 49 | 0.040 |
Why?
|
| Electrophysiology | 2 | 1993 | 160 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2019 | 75 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2019 | 36 | 0.040 |
Why?
|
| Motor Activity | 1 | 2003 | 621 | 0.040 |
Why?
|
| Potassium | 3 | 1985 | 168 | 0.040 |
Why?
|
| Sodium | 3 | 1985 | 161 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 51 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 145 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2006 | 282 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2019 | 87 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1553 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 1026 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2019 | 129 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1999 | 289 | 0.040 |
Why?
|
| Drug Implants | 1 | 1998 | 19 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 737 | 0.040 |
Why?
|
| Staurosporine | 1 | 1998 | 19 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2019 | 193 | 0.040 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 1998 | 11 | 0.040 |
Why?
|
| Glutamates | 1 | 1998 | 41 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1998 | 26 | 0.040 |
Why?
|
| Kainic Acid | 1 | 1998 | 44 | 0.040 |
Why?
|
| Brimonidine Tartrate | 3 | 1992 | 13 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2002 | 30 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 1998 | 65 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 1999 | 649 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 1998 | 206 | 0.040 |
Why?
|
| Tonometry, Ocular | 1 | 1996 | 11 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 619 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 1998 | 236 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2016 | 16 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 852 | 0.030 |
Why?
|
| Models, Biological | 2 | 2014 | 981 | 0.030 |
Why?
|
| Kinetics | 1 | 1998 | 1047 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 34 | 0.030 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 1995 | 6 | 0.030 |
Why?
|
| Substance P | 1 | 1995 | 39 | 0.030 |
Why?
|
| Timolol | 2 | 1985 | 10 | 0.030 |
Why?
|
| Cadaver | 1 | 2015 | 136 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1998 | 332 | 0.030 |
Why?
|
| Aminobutyrates | 1 | 1995 | 94 | 0.030 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2000 | 2358 | 0.030 |
Why?
|
| Receptors, Serotonin | 2 | 2003 | 74 | 0.030 |
Why?
|
| Endosomes | 1 | 2014 | 45 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2014 | 47 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 2014 | 67 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 1995 | 210 | 0.030 |
Why?
|
| Vasodilation | 1 | 1994 | 85 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 1993 | 2 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 97 | 0.030 |
Why?
|
| Ion Transport | 1 | 1993 | 26 | 0.030 |
Why?
|
| Endothelium | 1 | 2013 | 98 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 2013 | 37 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 127 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 132 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2006 | 447 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1992 | 32 | 0.030 |
Why?
|
| Ricin | 1 | 1992 | 6 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2012 | 54 | 0.030 |
Why?
|
| Brain | 1 | 2003 | 2176 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2012 | 99 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 101 | 0.030 |
Why?
|
| Plasmids | 1 | 2013 | 258 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2013 | 326 | 0.030 |
Why?
|
| Benzazepines | 1 | 1992 | 104 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1994 | 317 | 0.020 |
Why?
|
| Indomethacin | 1 | 1992 | 107 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1999 | 3705 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2800 | 0.020 |
Why?
|
| Quality of Life | 1 | 2019 | 1515 | 0.020 |
Why?
|
| Domperidone | 1 | 1990 | 11 | 0.020 |
Why?
|
| Retinal Artery Occlusion | 1 | 1990 | 7 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 1990 | 169 | 0.020 |
Why?
|
| Guanidines | 1 | 2009 | 32 | 0.020 |
Why?
|
| Urea | 1 | 2009 | 51 | 0.020 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1990 | 87 | 0.020 |
Why?
|
| Ganglionectomy | 1 | 1989 | 1 | 0.020 |
Why?
|
| Permeability | 1 | 2009 | 131 | 0.020 |
Why?
|
| Conjunctiva | 1 | 1988 | 16 | 0.020 |
Why?
|
| Keratitis | 1 | 1988 | 20 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 1988 | 150 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 420 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 2009 | 75 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 262 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.020 |
Why?
|
| Piperazines | 1 | 2009 | 206 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 902 | 0.020 |
Why?
|
| Cebus | 1 | 1987 | 9 | 0.020 |
Why?
|
| Neutrophils | 1 | 1988 | 204 | 0.020 |
Why?
|
| Retinol-Binding Proteins | 1 | 2007 | 28 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 8912 | 0.020 |
Why?
|
| Photoreceptor Cells | 1 | 2007 | 62 | 0.020 |
Why?
|
| Peptide Synthases | 1 | 2006 | 13 | 0.020 |
Why?
|
| Transcription Initiation Site | 1 | 2006 | 11 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2006 | 67 | 0.020 |
Why?
|
| Autophagy-Related Proteins | 1 | 2006 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2006 | 56 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2006 | 47 | 0.020 |
Why?
|
| Cytosol | 1 | 2006 | 123 | 0.020 |
Why?
|
| Genome | 1 | 2006 | 54 | 0.020 |
Why?
|
| Spleen | 1 | 2007 | 301 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 1998 | 7029 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 368 | 0.020 |
Why?
|
| Ions | 1 | 1986 | 50 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2006 | 251 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2007 | 411 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 357 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 492 | 0.020 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 1985 | 4 | 0.020 |
Why?
|
| Peptide Elongation Factors | 1 | 2005 | 1 | 0.020 |
Why?
|
| Body Fluids | 1 | 1985 | 41 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2005 | 36 | 0.020 |
Why?
|
| Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide | 1 | 1984 | 1 | 0.020 |
Why?
|
| Butaclamol | 1 | 1984 | 2 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 1985 | 102 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 742 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 1984 | 87 | 0.020 |
Why?
|
| Haloperidol | 1 | 1984 | 95 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1083 | 0.010 |
Why?
|
| Chlorine | 1 | 1985 | 76 | 0.010 |
Why?
|
| Pressure | 1 | 2004 | 252 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2004 | 238 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 489 | 0.010 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2003 | 1 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 249 | 0.010 |
Why?
|
| Stainless Steel | 1 | 2003 | 31 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 579 | 0.010 |
Why?
|
| Solutions | 1 | 2003 | 115 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 597 | 0.010 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 34 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 500 | 0.010 |
Why?
|
| Phloretin | 1 | 1982 | 1 | 0.010 |
Why?
|
| Phlorhizin | 1 | 1982 | 1 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2003 | 152 | 0.010 |
Why?
|
| Choroid | 1 | 1982 | 22 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 306 | 0.010 |
Why?
|
| Titanium | 1 | 2003 | 118 | 0.010 |
Why?
|
| Kringles | 1 | 2002 | 3 | 0.010 |
Why?
|
| Water | 1 | 2003 | 230 | 0.010 |
Why?
|
| Retinal Neovascularization | 1 | 2002 | 7 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 124 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2002 | 144 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 55 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2002 | 179 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 541 | 0.010 |
Why?
|
| Hyperoxia | 1 | 2001 | 27 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 718 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 171 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2001 | 396 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1995 | 27 | 0.010 |
Why?
|
| Medetomidine | 1 | 1990 | 6 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1990 | 19 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1990 | 163 | 0.010 |
Why?
|
| Ganglia, Sympathetic | 1 | 1989 | 4 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 1989 | 25 | 0.010 |
Why?
|
| Injections | 1 | 1989 | 119 | 0.010 |
Why?
|
| Imidazoles | 1 | 1990 | 175 | 0.010 |
Why?
|
| Anesthesia | 1 | 1990 | 120 | 0.000 |
Why?
|
| Heart Rate | 1 | 1989 | 568 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1989 | 1451 | 0.000 |
Why?
|